Proteasome-mediated destruction of the cyclin A/cyclin-dependent kinase 2 complex suppresses tumor cell growth in vitro and in vivo

Cancer Research

Volumn 64, Issue 11, 2004, Pages 3949-3957

  Chen, Wei ^a   Lee, Jeongwu ^a   Cho, Steve Y ^a   Fine, Howard A ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC PROTEIN; CYCLIN A; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; F BOX PROTEIN; PROTEASOME; PROTEIN P21;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER THERAPY; CONTROLLED STUDY; DRUG TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; TUMOR CELL; TUMOR GROWTH; UBIQUITINATION;

ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BETA-TRANSDUCIN REPEAT-CONTAINING PROTEINS; CARRIER PROTEINS; CDC2-CDC28 KINASES; CELL DIVISION; CELL LINE, TUMOR; CYCLIN A; CYCLIN-DEPENDENT KINASE 2; CYSTEINE ENDOPEPTIDASES; FEMALE; GLIOMA; HELA CELLS; HUMANS; MEMBRANE PROTEINS; MICE; MICE, NUDE; MULTIENZYME COMPLEXES; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN ENGINEERING; RECOMBINANT FUSION PROTEINS; TRANSDUCTION, GENETIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 2542623585     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-3906     Document Type: Article

References (66)

1. Ortega S, Malumbres M, Barbacid M. Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta 2002;1602:73-87.
2. Sausville EA. Complexities in the development of cyclin-dependent kinase inhibitor drugs. Trends Mol Med 2002;8:S32-7.
3. Malumbres M, Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 2001;1:222-31.
4. Sherr CJ. Cell cycle control and cancer. Harvey Lect 2000;96:73-92.
5. 1-phase progression. Genes Dev 1999;13:1501-12.
6. Malumbres M, Hunt SL, Sotillo R, et al. Driving the cell cycle to cancer. Adv Exp. Med Biol 2003;532:1-11.
7. Kitagawa M, Saitoh S, Ogino H, et al. cdc2-like kinase is associated with the retinoblastoma protein. Oncogene 1992;7:1067-74.
8. Lundberg AS, Weinberg RA. Functional inactivation of the refinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol Cell Biol 1998;18:753-61.
9. Knudsen ES, Wang JY. Differential regulation of retinoblastoma protein function by specific Cdk phosphorylation sites. J Biol Chem 1996;271:8313-20.
10. Cheng L, Rossi F, Fang W, Mori T, Cobrinik D. Cdk2-dependent phosphorylation and functional inactivation of the pRB-related p130 protein in pRB(-), p161NK4A(+) tumor cells. J Biol Chem 2000;275:30317-25.
11. Connell-Crowley L, Harper JW, Goodrich DW. Cyclin D1/Cdk4 regulates retinoblastoma protein-mediated cell cycle arrest by site-specific phosphorylation. Mol Biol Cell 1997;8:287-301.
12. 1 cyclin-associated kinases. Proc Natl Acad Sci USA 1996;93:4633-7.
13. Knudsen ES, Wang JY. Dual mechanisms for the inhibition of E2F binding to RB by cyclin-dependent kinase-mediated RB phosphorylation. Mol Cell Biol 1997;17:5771-83.
14. Shan B, Chang CY, Jones D, Lee WH. The transcription factor E2F-1 mediates the autoregulation of RB gene expression. Mol Cell Biol 1994;14:299-309.
15. Xiao B, Spencer J, Clements A, et al. Crystal structure of the retinoblastoma tumor suppressor protein bound to E2F and the molecular basis of its regulation. Proc Natl Acad Sci USA 2003;100:2363-8.
16. Neuman E, Flemington EK, Sellers WR, Kaelin WG Jr. Transcription of the E2F-1 gene is rendered cell cycle dependent by E2F DNA-binding sites within its promoter. Mol Cell Biol 1994;14:6607-15.
17. Hsiao KM, McMahon SL, Famham PJ. Multiple DNA elements are required for the growth regulation of the mouse E2F1 promoter. Genes Dev 1994;8:1526-37.
18. Johnson DG, Ohtani K, Nevins JR. Autoregulatory control of E2F1 expression in response to positive and negative regulators of cell cycle progression. Genes Dev 1994;8:1514-25.
19. Dynlacht BD, Flores O, Lees JA, Harlow E. Differential regulation of E2F transactivation by cyclin/cdk2 complexes. Genes Dev 1994;8:1772-86.
20. Weintraub SJ, Prater CA, Dean DC. Retinoblastoma protein switches the E2F site from positive to negative element. Nature (Lond.) 1992;358:259-61.
21. Johnson DG, Schwarz JK, Cress WD, Nevins JR. Expression of transcription factor E2F1 induces quiescent cells to enter S phase. Nature (Lond.) 1993;365:349-52.
22. Nevins JR. The Rb/E2F pathway and cancer. Hum Mol Genet 2001;10:699-703.
23. 1 cyclin-dependent kinase complexes in vivo. Mol Cell Biol 2001;21:4773-84.
24. Chen YN, Sharma SK, Ramsey TM, et al. Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists. Proc Natl Acad Sci USA 1999;96:4325-9.
25. Krek W, Ewen ME, Shirodkar S, Arany Z, Kaelin WG Jr, Livingston DM. Negative regulation of the growth-promoting transcription factor E2F-1 by a stably bound cyclin A-dependent protein kinase. Cell 1994;78:161-72.
26. Krek W, Xu G, Livingston DM. Cyclin A-kinase regulation of E2F-1 DNA binding function underlies suppression of an S-phase checkpoint. Cell 1995;83:1149-58.
27. Xu M, Sheppard KA, Peng CY, Yee AS, Piwnica-Worms H. Cyclin A/CDK2 binds directly to E2F-1 and inhibits the DNA-binding activity of E2F-1/DP-1 by phosphorylation. Mol Cell Biol 1994;14:8420-31.
28. Adams PD, Sellers WR, Sharma SK, Wu AD, Nalin CM, Kaelin WG Jr. Identification of a cyclin-cdk2 recognition motif present in substrates and p21-like cyclin-dependent kinase inhibitors. Mol Cell Biol 1996;16:6623-33.
29. Sellers WR, Kaelin WG Jr. Role of the retinoblastoma protein in the pathogenesis of human cancer. J Clin Oncol 1997;15:3301-12.
30. Strauss M, Lukas J, Bartek J. Unrestricted cell cycling and cancer. Nat Med 1995;1:1245-6.
31. Sherr CJ. Cancer cell cycles. Science (Wash. DC) 1996;274:1672-7.
32. Mendoza N, Fong S, Marsters J, Koeppen H, Schwall R, Wickramasinghe D. Selective cyclin-dependent kinase 2/cyclin A antagonists that differ from ATP site inhibitors block tumor growth. Cancer Res 2003;63:1020-4.
33. Lane ME, Yu B, Rice A, et al. A novel cdk2-selective inhibitor, SU9516, induces apoptosis in colon carcinoma cells. Cancer Res 2001;61:6170-7.
34. Qin XQ, Livingston DM, Kaelin WG Jr, Adams PD. Deregulated transcription factor E2F-1 expression leads to S-phase entry and p53-mediated apoptosis. Proc Natl Acad Sci USA 1994;91:10918-22.
35. Wu L, Timmers C, Maiti B, et al. The E2F1-3 transcription factors are essential for cellular proliferation. Nature (Lond.) 2001;414:457-62.
36. Fan J, Bertino JR. Functional roles of E2F in cell cycle regulation. Oncogene 1997;14:1191-200.
37. Stevens C, La Thangue NB. A new role for E2F-1 in checkpoint control. Cell Cycle 2003;2:435-7.
38. Hallstrom TC, Nevins JR. Specificity in the activation and control of transcription factor E2F-dependent apoptosis. Proc Natl Acad Sci USA 2003;100:10848-53
39. Alexander K, Yang HS, Hinds PW. pRb inacfivation in senescent cells leads to an E2F-dependent apoptosis requiring p73. Mol Cancer Res 2003;1:716-28.
40. Rogoff HA, Pickering MT, Debafis ME, Jones S, Kowalik TF. E2F-1 induces phosphorylation of p53 that is coincident with p53 accumulation and apoptosis. Mol Cell Biol 2002;22:5308-18.
41. Stiewe T, Putzer BM. Role of the p53-homologue p73 in E2F1-induced apoptosis. Nat Genet 2000;26:464-9.
42. Irwin M, Marin MC, Phillips AC, et al. Role for the p53 homologue p73 in E2F-1-induced apoptosis. Nature (Lond.) 2000;407:645-8.
43. Phillips AC, Ernst MK, Bates S, Rice NR, Vousden KH. E2F-1 potentiates cell death by blocking antiapoptotic signaling pathways. Mol Cell 1999;4:771-81.
44. Hsieh JK, Fredersdorf S, Kouzarides T, Martin K, Lu X. E2F1-induced apoptosis requires DNA binding but not transactivation and is inhibited by the retinoblastoma protein through direct interaction. Genes Dev 1997;11:1840-52.
45. Fueyo J, Gomez-Manzano C, Yung WK, et al. Overexpression of E2F-1 in glioma triggers apoptosis and suppresses tumor growth in vitro and in vivo. Nat Med 1998;4:685-90.
46. De Azevedo WF Jr, Mueller-Dieckmann HJ, Schulze-Gahmen U, Worland PJ, Sausville E, Kim SH. Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proc Natl Acad Sci USA 1996;93:2735-40.
47. 1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res 1996;56:2973-8.
48. Russo AA, Jeffrey PD, Pavletich NP. Structural basis of cyclin-dependent kinase activation by phosphorylation. Nat Struct Biol 1996;3:696-700.
49. Schulman BA, Lindstrom DL, Harlow E. Substrate recruitment to cyclin-dependent kinase 2 by a multipurpose docking site on cyclin A. Proc Natl Acad Sci USA 1998;95:10453-8.
50. Russo AA, Jeffrey PD, Patten AK, Massague J, Pavletich NP. Crystal structure of the p27Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex. Nature (Lond.) 1996;382:325-31.
51. Tetsu O, McCormick F. Proliferation of cancer cells despite CDK2 inhibition. Cancer Cell 2003;3:233-45.
52. Hinds PW. Cdk2 dethroned as master of S-phase entry. Cancer Cell 2003;3:305-7.
53. Ortega S, Prieto I, Odajima J, et al. Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice. Nat Genet 2003;35:25-31.
54. Deshaies RJ. SCF and Cullin/Ring H2-based ubiquitin ligases. Annu Rev Cell Dev. Biol 1999;15:435-67.
55. Zhou P, Howley PM. Ubiquitination and degradation of the substrate recognition subunits of SCF ubiquitin-protein ligases. Mol Cell 1998;2:571-80.
56. Margottin F, Bour SP, Durand H, et al. A novel human WD protein, h-β TrCp, that interacts with HIV-1 Vpu connects CD4 to the ER degradation pathway through an F-box motif. Mol Cell 1998;1:565-74.
57. Zhou P, Bogacki R, McReynolds L, Howley PM. Harnessing the ubiquitination machinery to target the degradation of specific cellular proteins. Mol Cell 2000;6:751-6.
58. Sakamoto KM, Kim KB, Kumagai A, Mercurio F, Crews CM, Deshaies RJ. Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. Proc Natl Acad Sci USA 2001;98:8554-9.
59. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 1998;95:2509-14.
60. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature (Lond.) 2001;24:494-8.
61. Lowe ED, Tews I, Cheng KY, et al. Specificity determinants of recruitment peptides bound to phospho-CDK2/cyclin A. Biochemistry 2002;41:15625-34.
62. Brown NR, Noble ME, Lawrie AM, et al. Effects of phosphorylation of threonine 160 on cyclin-dependent kinase 2 structure and activity. J Biol Chem 1999;274:8746-56.
63. Strausfeld U, Labbe JC, Fesquet D, et al. Dephosphorylation and activation of a p34cdc2/cyclin B complex in vitro by human CDC25 protein, Nature (Lond.) 1991;351:242-5.
64. Jackson AL, Bartz SR, Schelter J, et al. Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol 2003;21:635-7.
65. La Sala D, Macaluso M, Trimarchi C, Giordano A, Cinti C. Triggering of p73-dependent apoptosis in osteosarcoma is under the control of E2Fs-pRb2/p130 complexes. Oncogene 2003;22:3518-29,
66. Rodicker F, Stiewe T, Zimmermann S, Putzer BM. Therapeutic efficacy of E2F1 in pancreatic cancer correlates with TP73 induction. Cancer Res 2001;61:7052-5.